$TCRT
Alaunos Therapeutics, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022017225 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $2.911M $0.00 $0.00
YoY Change 631.41%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.282M $3.429M $3.505M
YoY Change -59.84% -62.19% -57.4%
% of Gross Profit
Research & Development $7.893M $5.937M $5.580M
YoY Change -45.64% -56.25% -58.16%
% of Gross Profit
Depreciation & Amortization $691.0K $685.0K $689.0K
YoY Change 2.67% 0.88% 27.59%
% of Gross Profit
Operating Expenses $11.18M $9.233M $9.085M
YoY Change -50.76% -59.22% -57.87%
Operating Profit -$8.264M -$9.233M -$9.085M
YoY Change -62.94% -59.22% -57.87%
Interest Expense $841.0K $740.0K -$683.0K
YoY Change -289.41%
% of Operating Profit
Other Income/Expense, Net -$587.0K $41.00K -$703.0K
YoY Change 34.32% -232.26% -7911.11%
Pretax Income -$8.851M -$9.932M -$9.788M
YoY Change -61.07% -56.19% -54.59%
Income Tax
% Of Pretax Income
Net Earnings -$8.851M -$9.932M -$9.788M
YoY Change -61.07% -56.19% -54.59%
Net Earnings / Revenue -304.05%
Basic Earnings Per Share -$0.04 -$0.05 -$0.05
Diluted Earnings Per Share -$0.04 -$0.05 -$45.54K
COMMON SHARES
Basic Shares Outstanding 216.2M 215.0M 216.1M
Diluted Shares Outstanding 215.1M 215.0M 214.9M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $37.81M $60.01M $68.26M
YoY Change -58.78% -21.81% -31.78%
Cash & Equivalents $37.80M $60.00M $68.30M
Short-Term Investments
Other Short-Term Assets $14.79M $1.350M $1.517M
YoY Change 345.53% -73.19% -80.16%
Inventory
Prepaid Expenses
Receivables $2.911M $0.00 $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $55.51M $61.36M $69.77M
YoY Change -42.51% -31.37% -38.1%
LONG-TERM ASSETS
Property, Plant & Equipment $9.050M $9.671M $10.31M
YoY Change -22.4% -16.67% -33.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $500.0K $500.0K $626.0K
YoY Change 24900.0% 3025.0% 98.73%
Total Long-Term Assets $11.84M $12.57M $15.22M
YoY Change -31.2% -27.58% -3.44%
TOTAL ASSETS
Total Short-Term Assets $55.51M $61.36M $69.77M
Total Long-Term Assets $11.84M $12.57M $15.22M
Total Assets $67.34M $73.93M $84.99M
YoY Change -40.8% -30.75% -33.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.984M $474.0K $605.0K
YoY Change 35.61% -51.73% -85.56%
Accrued Expenses $7.675M $5.725M $5.891M
YoY Change -45.03% -51.67% -60.12%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $22.67M $20.05M $13.99M
YoY Change 88.32%
Total Short-Term Liabilities $32.87M $26.78M $21.23M
YoY Change 16.67% 96.98% 11.99%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $4.472M $10.32M
YoY Change -100.0%
Other Long-Term Liabilities $28.00K $28.00K $4.312M
YoY Change -99.41% -99.43% 11.42%
Total Long-Term Liabilities $28.00K $4.500M $10.32M
YoY Change -99.77% -7.99% 166.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.87M $26.78M $21.23M
Total Long-Term Liabilities $28.00K $4.500M $10.32M
Total Liabilities $35.23M $33.75M $35.87M
YoY Change -21.8% 82.6% 57.11%
SHAREHOLDERS EQUITY
Retained Earnings -$871.5M -$862.6M -$852.6M
YoY Change 4.86% 6.72%
Common Stock $903.6M $902.8M $901.8M
YoY Change 0.42% 0.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $32.11M $40.18M $49.12M
YoY Change
Total Liabilities & Shareholders Equity $67.34M $73.93M $84.99M
YoY Change -40.8% -30.75% -33.84%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$8.851M -$9.932M -$9.788M
YoY Change -61.07% -56.19% -54.59%
Depreciation, Depletion And Amortization $691.0K $685.0K $689.0K
YoY Change 2.67% 0.88% 27.59%
Cash From Operating Activities -$6.145M -$8.187M -$7.770M
YoY Change -35.84% -61.84% -49.26%
INVESTING ACTIVITIES
Capital Expenditures -$14.00K -$57.00K $29.00K
YoY Change -96.22% -96.96% -95.96%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$14.00K -$57.00K -$29.00K
YoY Change -96.22% -96.96% -95.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $0.00
YoY Change
Cash From Financing Activities -2.107M 0.000 0.000
YoY Change -108.45% -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -6.145M -8.187M -7.770M
Cash From Investing Activities -14.00K -57.00K -29.00K
Cash From Financing Activities -2.107M 0.000 0.000
Net Change In Cash -8.266M -8.244M -7.799M
YoY Change -155.18% -64.63% -48.05%
FREE CASH FLOW
Cash From Operating Activities -$6.145M -$8.187M -$7.770M
Capital Expenditures -$14.00K -$57.00K $29.00K
Free Cash Flow -$6.131M -$8.130M -$7.799M
YoY Change -33.41% -58.47% -51.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
0
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001107421
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33038
dei Entity Registrant Name
EntityRegistrantName
Alaunos Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1475642
dei Entity Address Address Line1
EntityAddressAddressLine1
8030 El Rio Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77054
dei City Area Code
CityAreaCode
346
dei Local Phone Number
LocalPhoneNumber
355-4099
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
TCRT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.045
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
216174542
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60011000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76054000
CY2022Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
0
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1111000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1350000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1666000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
61361000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
78831000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9671000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10941000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2357000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4420000
CY2022Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
42000
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
42000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
500000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
631000
CY2022Q2 us-gaap Assets
Assets
73931000
CY2021Q4 us-gaap Assets
Assets
94865000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
474000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1368000
CY2022Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
20051000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
7868000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5725000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6076000
CY2022Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
525000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
729000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
26775000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16041000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4472000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16250000
CY2022Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
2476000
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
4518000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
28000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2022Q2 us-gaap Liabilities
Liabilities
33751000
CY2021Q4 us-gaap Liabilities
Liabilities
36809000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
420000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
216174542
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
216174542
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
216127443
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
216127443
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
216000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
216000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
902536000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
900693000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-862572000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-842852000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
40180000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
58057000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
73931000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
94865000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5937000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13570000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11518000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26906000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3429000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9069000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6935000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17296000
CY2022Q2 tcrt Gain Loss On Operating Lease Modification
GainLossOnOperatingLeaseModification
133000
CY2021Q2 tcrt Gain Loss On Operating Lease Modification
GainLossOnOperatingLeaseModification
0
tcrt Gain Loss On Operating Lease Modification
GainLossOnOperatingLeaseModification
133000
tcrt Gain Loss On Operating Lease Modification
GainLossOnOperatingLeaseModification
0
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
9233000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
22639000
us-gaap Operating Expenses
OperatingExpenses
18320000
us-gaap Operating Expenses
OperatingExpenses
44202000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9233000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22639000
us-gaap Operating Income Loss
OperatingIncomeLoss
-18320000
us-gaap Operating Income Loss
OperatingIncomeLoss
-44202000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1036000
CY2022Q2 us-gaap Interest Expense
InterestExpense
740000
CY2021Q2 us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
1425000
us-gaap Interest Expense
InterestExpense
0
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
41000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-31000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
25000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-22000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9932000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-22670000
us-gaap Net Income Loss
NetIncomeLoss
-19720000
us-gaap Net Income Loss
NetIncomeLoss
-44224000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9932000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22670000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19720000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-44224000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
214998893
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
214998893
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
214426406
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
214426406
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
214972876
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
214972876
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
214191839
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
214191839
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
49122000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
990000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9932000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
40180000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
58057000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1843000
us-gaap Net Income Loss
NetIncomeLoss
-19720000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
40180000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
105641000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5290000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-22670000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
88281000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
123982000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7486000
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000
us-gaap Net Income Loss
NetIncomeLoss
-44224000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
88281000
us-gaap Net Income Loss
NetIncomeLoss
-19720000
us-gaap Net Income Loss
NetIncomeLoss
-44224000
us-gaap Depreciation
Depreciation
1374000
us-gaap Depreciation
Depreciation
1219000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
405000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
1843000
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
7486000
tcrt Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
-2196000
tcrt Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
721000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
133000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-1111000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
2961000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-316000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5820000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-131000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-493000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-894000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
22000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-368000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4742000
tcrt Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-2246000
tcrt Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
843000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
28000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15957000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36765000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
86000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2594000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-86000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2594000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1036000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1036000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16043000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-38323000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76054000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115069000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60011000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76746000
us-gaap Interest Paid Net
InterestPaidNet
1002000
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
17000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
258000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60000000.0
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-862600000
tcrt Interest Expense Amortized Date
InterestExpenseAmortizedDate
2023-08-01
CY2022Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
700000
us-gaap Interest Expense Debt
InterestExpenseDebt
1400000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">these </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.71
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3961735
CY2022Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
24523000
CY2022Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
20051000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4472000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
34168665
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33988064
CY2022Q2 tcrt Gain Loss On Modification Of Lease
GainLossOnModificationOfLease
100000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.33
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10086635
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.97
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11M12D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1611000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2955111
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
990000
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
5290000
us-gaap Share Based Compensation
ShareBasedCompensation
1844000
us-gaap Share Based Compensation
ShareBasedCompensation
7486000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
692500
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
3382500
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.48
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
41500
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.27
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
4395438
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.44
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0283
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0354
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0115
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0163
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0354
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0009
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0115
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7858
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8297
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7408
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7449
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8297
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7292
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7480
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10665869
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.87
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
3382500
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.28
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y10M13D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
89000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4410312
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.85
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y6M10D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
15780200
CY2019Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
52500000

Files In Submission

Name View Source Status
0000950170-22-017225-index-headers.html Edgar Link pending
0000950170-22-017225-index.html Edgar Link pending
0000950170-22-017225.txt Edgar Link pending
0000950170-22-017225-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img101517463_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tcrt-20220630.htm Edgar Link pending
tcrt-20220630.xsd Edgar Link pending
tcrt-20220630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
tcrt-20220630_htm.xml Edgar Link completed
tcrt-ex10_1.htm Edgar Link pending
tcrt-ex10_2.htm Edgar Link pending
tcrt-ex14_1.htm Edgar Link pending
tcrt-ex31_1.htm Edgar Link pending
tcrt-ex32_1.htm Edgar Link pending
tcrt-ex3_1.htm Edgar Link pending
tcrt-20220630_lab.xml Edgar Link unprocessable
tcrt-20220630_pre.xml Edgar Link unprocessable
tcrt-20220630_cal.xml Edgar Link unprocessable